Pharmaceutical Executive
The Promise Of Translational Medicine
Pharmaceutical Executive-02-01-2011
Novartis' Gilenya is a step forward in treating Multiple Sclerosis. But generating increased compliance is another story
Pharmaceutical Executive
Increased efficiency and lower operating costs for both CROs and vendors can be achieved by eliminating activities
To manage through a resource-constrained environment, it is essential to get the most out of procurement planning
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
2
Merck Planning $70 Billion Investment for US Expansion
3
Amazon and WeightWatchers Partner for DTC Weight Loss Medication Offerings
4
FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps
5
